Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial
by Yeming Wang MD, Dingyu Zhang MD, Prof Guanhua Du PhD, Prof Roghui Du MD, Prof Jianping Zhao MD, Prof Yang Jin MDThe Lancet - 29th April 2020 No specific antiviral drug has been proven effective for treatment of patients with severe coronavirus disease 2019 (COVID-19). Remdesivir (GS-5734), a nucleoside analogue prodrug, has inhibitory effects on pathogenic animal and human coronaviruses, including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in vitro, and inhibits Middle East respiratory syndrome coronavirus, SARS-CoV-1, and SARS-CoV-2 replication in animal models. Read full article
30th April 2020 •
comment
A rapid research needs appraisal methodology to identify evidence gaps to inform clinical research priorities in response to outbreaks—results from the Lassa fever pilot
by Louise Sigfrid, Alex Salam and Peter Horby
1st July 2019 •
comment